Pharmacological modulation of eicosanoid levels and hyperalgesia in yeast-induced inflammation.
Injection of brewer's yeast into the rat paw results in edema and a subsequent hyperalgesia. The edema was accompanied by an increase in 5-lipoxygenase products, and the hyperalgesia coincided with the formation of both cyclooxygenase and 5-lipoxygenase products. When administered perorally, indomethacin inhibited cyclooxygenase product formation, phenidone inhibited 5-lipoxygenase product formation, and 3-amino-1-(m-[trifluoromethyl]-phenyl)-2-pyrazoline (BW 755C) inhibited formation of products of both pathways. These compounds were also effective analgesic agents. The correlation of these effects with the suppression of hyperalgesia suggests the participation of products from both cyclooxygenase and 5-lipoxygenase pathways in the mediation of hyperalgesia.
D015772:4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine; D000818:Animals; D001094:Arachidonate 5-Lipoxygenase / Q000378:metabolism; D015232:Dinoprostone; D004487:Edema / Q000150:complications / Q000378:metabolism*; D004537:Eicosanoic Acids / Q000378:metabolism*; D006930:Hyperalgesia / Q000150:complications / Q000378:metabolism*; D006941:Hyperesthesia / Q000378:metabolism*; D009181:Mycoses / Q000150:complications / Q000378:metabolism*; D011451:Prostaglandin-Endoperoxide Synthases / Q000378:metabolism; D011458:Prostaglandins E / Q000378:metabolism; D011720:Pyrazoles / Q000494:pharmacology; D051381:Rats; D012441:Saccharomyces cerevisiae; D013929:Thromboxane B2 / Q000378:metabolism
D004537:Eicosanoic Acids; D011458:Prostaglandins E; D011720:Pyrazoles; D013929:Thromboxane B2; D015772:4,5-Dihydro-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-3-amine; D001094:Arachidonate 5-Lipoxygenase; D011451:Prostaglandin-Endoperoxide Synthases; D015232:Dinoprostone